ADHD（注意欠如・多動症）の世界市場：治療タイプ別、年齢層別、ADHDサブタイプ別、地域別、範囲および予測

ADHD（注意欠如・多動症）の市場規模と予測

ADHD（注意欠如・多動症）の世界市場規模は、2024年に237億4,000万米ドルと評価され、2031年には389億6,000万米ドルに達すると予測され、2024年から2031年までのCAGRは7.05%で成長します。ADHD（注意欠如・多動症）は、日常生活に支障をきたす不注意、多動性、衝動性が持続する神経発達障害です。主に小児が罹患するが、成人期まで持続することもあり、学業成績、仕事、人間関係など生活の多くの側面に影響を及ぼします。ADHDの管理介入には、薬物療法、行動療法、集中力、整理整頓、行動を改善するように調整された教育的支援が含まれます。

ADHD治療の将来は、デジタルヘルスソリューションの進歩、個別化医療、成人ADHDに関する研究の増加により、有望視されています。これらの開発により、診断精度、治療効果、患者全体の転帰が改善すると期待されています。

ADHD（注意欠如・多動症）の世界市場力学

世界のADHD（注意欠如・多動症）市場を形成している主な市場力学

主な市場促進要因

認識と支持の高まり：

ADHDに対する認識と擁護活動の高まりが市場を前進させています。例えば、2024年8月、National Resource Center on ADHDは、ADHD啓発月間キャンペーンを開始し、ADHDに対する一般市民や専門家の理解を著しく高め、その結果、診断率や治療導入率が上昇しました。

診断技術の進歩：

新しい診断ツールや技術は、ADHD診断の正確さと効率を向上させています。2024年7月、FDAは新しいデジタルADHD診断アプリを承認し、よりアクセスしやすく正確な評価が可能になり、市場成長の後押しになると期待されています。

治療選択肢の拡大：

新しく改良された薬や治療法は大きな推進力です。2024年9月、製薬会社が不注意と多動の両方の症状に対応する新規ADHD治療薬の発売を発表し、治療選択肢の拡大と市場成長の促進が期待されます。

政府の取り組みと資金援助：

ADHDの研究と治療に対する政府の支援と資金提供の拡大は、市場の成長を促進しています。例えば、欧州連合（EU）は2024年6月、治療戦略や支援システムの改善を目的として、ADHD研究プロジェクトへの助成金を増額しました。

主な課題

偏見と誤解：

認知度は高まっているもの、ADHDに対する偏見や誤解は依然として残っています。これは、診断や治療を受けることに消極的になり、患者に提供されるケアやサポートの質全体に影響を及ぼす可能性があります。

高額な治療費

：ADHDの薬物療法、治療、継続的な管理は、特に医療保険が限られている地域では、患者によっては法外な費用がかかることがあります。この経済的障壁は、必要な治療や支援サービスへのアクセスを制限する可能性があります。

診断基準のばらつき：

地域や医療制度によってADHDの診断基準や診療方法が異なるため、診断や治療に一貫性がなくなることがあります。このような標準化の欠如は、ADHD治療の信頼性と患者の転帰に影響を及ぼす可能性があります。

専門的治療への限られたアクセス：

ADHDを専門とするヘルスケア専門家は、特に地方や十分なサービスを受けていない地域では不足しています。この限られたアクセスは、タイムリーな診断と治療を妨げ、患者の転帰と市場全体の成長に影響を及ぼす可能性があります。

主な動向

認知度の向上と早期診断：

ヘルスケア専門家および一般市民のADHDに対する認識が高まるにつれ、診断はより早期に、より正確に行われるようになります。この動向は、教育キャンペーンや診断ツールの進歩によって助長され、その結果、発見率と治療率が向上します。

成人ADHDの診断増加

以前は見過ごされていた成人ADHDは、その有病率と影響に対する認識が高まるにつれて、より注目されるようになってきています。診断基準が改善され、成人ADHDの症状に対する理解が深まったことで、成人に対する診断や個別化された治療の選択肢が増えつつあります。

デジタルヘルスソリューションの統合：

モバイルアプリやオンライン治療プラットフォームなどのデジタルヘルス技術の利用は、ADHDの管理を改善します。これらのツールは、患者の治療へのアクセス、リアルタイムのモニタリング、個別化された介入を改善し、より良い転帰をもたらします。

マルチモーダル治療アプローチの拡大：

ADHD治療により包括的なアプローチを提供するために、薬物療法と行動療法を組み合わせる傾向が強まっています。このマルチモーダル戦略は、障害の複数の側面に対処することを目的としており、その結果、より効果的な管理が可能となり、患者のQOLが向上します。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 ADHD（注意欠如・多動症）市場：治療タイプ別

• 薬物療法
• 行動療法
• 複合療法

第5章 ADHD（注意欠如・多動症）市場：年齢層別

• 小児
• 成人

第6章 ADHD（注意欠如・多動症）市場：ADHDサブタイプ別

• 不注意優勢型
• 多動性-衝動性優勢型
• 複合型

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt plc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceuticals Inc.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Attention-Deficit Hyperactivity Disorder Market Size And Forecast

Global Attention Deficit Hyperactivity Disorder Market size was valued at USD 23.74 Billion in 2024 and is projected to reach USD 38.96 Billion by 2031 , growing at a CAGR of 7.05% from 2024 to 2031. Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder marked by persistent patterns of inattention, hyperactivity, and impulsivity that impair daily functioning. It primarily affects children, but it can persist into adulthood, affecting many aspects of life such as academic performance, work, and relationships. ADHD management interventions include medication, behavioral therapy, and educational support tailored to improve focus, organization, and behavior.

The future of ADHD treatment looks promising, thanks to advances in digital health solutions, personalized medicine, and increased research into adult ADHD. These developments are expected to improve diagnostic accuracy, treatment efficacy, and overall patient outcomes.

Global Attention Deficit Hyperactivity Disorder Market Dynamics

The key market dynamics that are shaping the global attention deficit hyperactivity disorder market include:

Key Market Drivers:

Increasing Awareness and Advocacy:

Growing awareness and advocacy efforts for ADHD are propelling the market forward. For instance, in August 2024, the National Resource Center on ADHD launched the ADHD Awareness Month campaign, which significantly increased public and professional understanding of the disorder, resulting in higher diagnosis rates and treatment adoption.

Advances in Diagnostic Technologies:

New diagnostic tools and technologies are improving the accuracy and efficiency of ADHD diagnosis. In July 2024, the FDA approved a new digital ADHD diagnostic app, promising more accessible and precise evaluations and expected to boost market growth.

Expansion of Treatment Options:

New and improved medications and therapies are a major driver. In September 2024, a pharmaceutical company announced the release of a novel ADHD medication that addresses both inattentive and hyperactive symptoms, broadening treatment options and driving market growth.

Government Initiatives and Funding:

Greater government support and funding for ADHD research and treatment are driving market growth. For instance, in June 2024, the European Union increased funding for ADHD research projects, with the goal of improving treatment strategies and support systems, which is expected to drive market growth in Europe and beyond.

Key Challenges:

Stigma and Misconceptions:

Despite growing awareness, stigma and misconceptions about ADHD remain. This can lead to reluctance to seek diagnosis and treatment, affecting the overall quality of care and support provided to patients.

High Cost of Treatment

: ADHD medications, therapies, and ongoing management can be prohibitively expensive for some patients, especially in areas with limited healthcare coverage. This financial barrier may limit access to necessary treatment and support services.

Variability in Diagnostic Criteria:

Differences in ADHD diagnostic criteria and practices between regions and healthcare systems can result in inconsistencies in diagnosis and treatment. This lack of standardization can have an impact on the reliability of ADHD treatment and patient outcomes.

Limited Access to Specialized Care:

There is a shortage of healthcare professionals who specialize in ADHD, especially in rural or underserved areas. This limited access can impede timely diagnosis and treatment, affecting patient outcomes and overall market growth.

Key Trends:

Increasing Awareness and Early Diagnosis:

As healthcare professionals and the general public become more aware of ADHD, diagnoses will be made earlier and more accurately. This trend is aided by educational campaigns and advances in diagnostic tools, which result in higher rates of detection and treatment.

Adult ADHD Diagnosis is Growing:

Adult ADHD, which was previously overlooked, is receiving more attention as awareness of its prevalence and impact grows. Improved diagnostic criteria and a better understanding of adult ADHD symptoms are leading to more diagnoses and personalized treatment options for adults.

Integration of Digital Health Solutions:

The use of digital health technologies, such as mobile apps and online therapy platforms, improves ADHD management. These tools improve patient access to treatment, real-time monitoring, and personalized interventions, resulting in better outcomes.

Expansion of Multimodal Treatment Approaches:

There is an increasing trend of combining medication with behavioral therapies to provide a more comprehensive approach to ADHD treatment. This multimodal strategy aims to address multiple aspects of the disorder, resulting in more effective management and higher patient quality of life.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Attention Deficit Hyperactivity Disorder Market Regional Analysis

Here is a more detailed regional analysis of the global attention deficit hyperactivity disorder market:

North America:

North America dominates the global attention deficit hyperactivity disorder (ADHD) market due to its well-established healthcare infrastructure, high rates of diagnosis, and wide range of treatment options. The region has a comprehensive support system that includes advanced medical facilities, research institutions, and a diverse range of ADHD medications and therapies. This robust healthcare ecosystem ensures that North America remains the leading market for ADHD treatment. For instance, in August 2024, the United States Food and Drug Administration (FDA) approved a new ADHD medication designed specifically for adults, cementing the region's position as a key market due to its strong regulatory framework and significant investment in ADHD research and treatment.

North America is also seeing rapid growth in the ADHD market. This growth is being driven by increased awareness of ADHD, improved diagnostic tools, and expanded access to both medication and behavioral therapies. In July 2024, the National Institute of Mental Health's (NIMH) increased funding for ADHD research are promoting advances in treatment and diagnostics. These efforts are not only improving care quality, but also contributing to the rapid growth of the region's ADHD market.

Asia Pacific:

Asia Pacific is the fastest-growing region in the global attention deficit hyperactivity disorder (ADHD) market, owing to rising awareness, improved diagnostic capabilities, and greater healthcare access. The rise in ADHD diagnosis in countries such as China, India, and Japan is being driven by increased public awareness and the adoption of international diagnostic guidelines. In June 2024, the Indian Ministry of Health launched a national awareness campaign for mental health disorders, including ADHD, which is expected to increase diagnosis rates and treatment accessibility in the region.

Furthermore, the Asia Pacific market is expanding rapidly due to advances in healthcare infrastructure and increased investment in mental health. For instance, in May 2024, the Chinese government announced a significant increase in funding for mental health services, including ADHD treatment, as part of a larger health reform agenda. This investment improves the availability of ADHD treatment options and promotes better diagnostic practices, thereby contributing to the region's rapid market growth.

Global Attention Deficit Hyperactivity Disorder Market: Segmentation Analysis

The Global Attention Deficit Hyperactivity Disorder Market is segmented on the basis of By Treatment Type, By Age Group, By Subtypes of ADHD, and By Geography.

Global Attention Deficit Hyperactivity Disorder Market, By Treatment Type

• Medication
• Behavioral Therapy
• Combined Therapy

Based on Treatment Type, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Medication, Behavioral Therapy, and Combined Therapy. Medication dominates the global ADHD market because it is the primary and most widely used treatment option, providing effective symptom management for a large number of patients. The fastest-growing segment is Combined Therapy, which is driven by a growing recognition of the benefits of combining medication and behavioral therapy for more comprehensive ADHD management and better patient outcomes.

Global Attention Deficit Hyperactivity Disorder Market, By Age Group

• Children
• Adults

Based on Age Group, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Children, Adults . Children are the dominant segment in the global ADHD market because the disorder is most commonly diagnosed during childhood, resulting in a greater number of cases and treatment options tailored to this age group. Adults are the fastest-growing segment, thanks to increased awareness of adult ADHD and improved diagnostic practices, which are detecting more cases of ADHD in previously undiagnosed adults.

Global Attention Deficit Hyperactivity Disorder Market, By Subtypes of ADHD

• Predominantly Inattentive Presentation
• Predominantly Hyperactive-Impulsive Presentation
• Combined Presentation

Based on Subtypes of ADHD, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Predominantly Inattentive Presentation, Predominantly Hyperactive-Impulsive Presentation, and Combined Presentation. The global ADHD market is dominated by Combined Presentation, which includes a wide range of symptoms and is frequently diagnosed due to its comprehensive nature. Predominantly Inattentive Presentation is the fastest-growing segment, with increased awareness of inattentiveness and its consequences, resulting in more diagnoses and treatment options for people who primarily exhibit inattentive symptoms.

Global Attention Deficit Hyperactivity Disorder Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Attention Deficit Hyperactivity Disorder Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America dominates the global Attention Deficit Hyperactivity Disorder (ADHD) market, owing to high diagnosis rates, robust healthcare infrastructure, and significant investments in ADHD treatment and research. Asia Pacific is the fastest-growing region in this market, owing to rising awareness, higher diagnosis rates, and greater access to healthcare services, particularly in emerging economies.

Key Players

• The "Global Attention Deficit Hyperactivity Disorder Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson Services, Inc., Lupin, Novartis AG, Mallinckrodt plc., Purdue Pharma LP, NEOS Therapeutics, Inc., Supernus Pharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Attention Deficit Hyperactivity Disorder Market: Recent Developments
• In September 2024, BrainTech Solutions launched ADHDScan, an innovative digital app for remote ADHD diagnosis. This tool uses AI algorithms to provide accurate assessments, with the goal of improving access to diagnostic services, particularly in underserved areas.
• In July 2024, The World Health Organization (WHO) launched a global ADHD awareness campaign to emphasize the importance of early diagnosis and treatment. This initiative is expected to raise public awareness and lead to increased diagnosis rates worldwide.
• In June 2024, the Behavioral Health Alliance expanded its online therapy platform to include ADHD-specific programs. This expansion makes therapeutic options more accessible to people with ADHD, which helps the market grow.
• In April 2024, MedCore Pharmaceuticals launched a personalized ADHD treatment program tailoring medications and therapies based on genetic tests. This personalized approach aims to improve treatment outcomes and is expected to gain popularity in the market.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Attention-Deficit Hyperactivity Disorder Market, By Treatment Type

• Medication
• Behavioral Therapy
• Combined Therapy

5. Attention-Deficit Hyperactivity Disorder Market, By Age Group

• Children
• Adults

6. Attention-Deficit Hyperactivity Disorder Market, By Subtypes of ADHD

• Predominantly Inattentive Presentation
• Predominantly Hyperactive-Impulsive Presentation
• Combined Presentation

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt plc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceuticals Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References